Events

­

Quark’s joint venture Riboquark announces the enrollment of the 1st ever Patient in China for a pivotal clinical trial with a siRNA drug candidate

November 13th, 2017|

RiboQuark Pharmaceutical Technology Co., Ltd., Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007.
Kunshan, China, 13/Nov/2017 – Kunshan RiboQuark Pharmaceutical Technology Co., Ltd. (“RiboQuark”), a Chinese-foreign equity joint venture and clinical stage pharmaceutical […]

Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

November 7th, 2017|

Fremont, CA – November 7, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced that positive results from a Phase 2 clinical study on its lead program QPI-1002 will be presented as an oral abstract at the […]

Quark Pharmaceuticals, Inc. Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting

November 4th, 2017|

 Fremont, CA – November 4, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, presented today at the late breaking plenary session of the American Society of Nephrology (ASN) / Kidney Week positive results from a Phase 2 clinical study, […]

Quark Pharmaceuticals, Inc. Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

November 1st, 2017|

Fremont, CA – November 1, 2017 – Quark Pharmaceuticals, Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNAi-based therapeutics for unmet medical needs, today announced that Phase 2 data on its lead program QPI-1002 will be presented as an oral abstract at the American Society of Nephrology (ASN) […]

Quark will present at Eurotides 2015, Maritim proArte Hotel, Berlin, Germany ,16-18 Nov 2015

August 23rd, 2015|

http://www.informa-ls.com/event/eurotides2015

Quark will present at 2015 American Transplant Congress, May 5, 2015

April 5th, 2015|

Relationship Between Delayed Graft Function (DGF) Severity and Predicted DGF Risk

E. Squiers,1 B. Irish,1 D. Odenheimer,1 S. Erlich,1 J. Grinyo, S. Feng, On Behalf of Quark DGF Study Investigators.

1Quark, Fremont
2UCSF, SF
3U of Barcelona, BCN, Spain.

Meeting: 2015 American Transplant Congress

Abstract number: 448

Keywords: Cadaveric organs, Graft function, Kidney transplantation, Outcome

 

http://www.atcmeetingabstracts.com/abstract/relationship-between-delayed-graft-function-dgf-severity-and-predicted-dgf-risk/

Quark will present at TIDES 2015, at the Town and Country Hotel in San Diego, CA, May 3-6, 2015

April 3rd, 2015|

Results of a Large Phase 2 siRNA Study: Target Expression Translates to Therapeutic Outcomes
Results of large (N=326) P2 study showed QPI-1002, a systemically administered siRNA targeting p53, significantly reduced the clinical endpoint of severity of delayed graft function post-transplant, especially in kidneys from older donors (p<0.016); which are known to have increased p53. A P3 […]

Quark will present at The 7th GTC Ocular Disease Drug Discovery Conference. San Diego, CA. March 18-19, 2015.

February 18th, 2015|

A Synthetic Chemically Modified siRNA Targeting Caspase 2 as a Therapeutic Agent for Ocular Neuroprotection

https://www.gtcbio.com/conferences/ocular-diseases-drug-discovery-speakers

Quark will present at Targeting Ocular Disorders. Boston, MA. October 6-7, 2014

September 6th, 2014|

A Synthetic Chemically Modified siRNA Targeting Caspase-2 as a Therapeutic Agent for Ocular europrotection
Elena Feinstein, M.D., Ph.D., CSO, Quark Pharmaceuticals
Caspase-2 is a pro-apoptotic gene specifically expressed and activated in retinal
ganglion cells following acute optic nerve injury or intraocular pressure increase.
Intravitreal administration of QPI1007 (a syntehticsiRNA targeting caspase-2)
demonstrated local RNA interference, lack of inflammatory effects and […]

Quark will present at 2014 World Transplant Congress July 26-31st 2014

July 26th, 2014|

Treatment with QPI-1002, a Short Interfering (SI) RNA for the

Prophylaxis of Delayed Graft Function. V. Peddi,1 L. Ratner,2 M.

Cooper,2 O. Gaber,2 S. Feng,2 P. Tso,2 V. Bowers,2 R. Naraghi,2 K. Budde,2

Polinsky,3 E. Squiers,3 S. Erlich,3 Study Investigators Group.2 1CPMC,

San Francisco, CA; 2Multiple Institutions; 3Quark Pharmaceuticals,

Fremont.

Introduction: Delayed graft function (DGF) can adversely affect deceased donor

renal transplant […]